Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and Eurasia
HYDERABAD, INDIA (May 22, 2012 ) – Suven Life Sciences Ltd (Suven) announces today that the grant of four (4) product patents, one (1) each from Japan (4886522), Australia (2008315309), Europe (2200980) and Eurasia (16015) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2024 and 2027.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a totalof five (5) granted patents from Japan, fourteen (14) from Australia, twelve (12) from Europe and ten (10) granted patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally” says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer’s disease and Schizophrenia.
For more information on Suven please visit our Web site at http://www.suven.com
Source: Suven Life Sciences